- The acquisition is Riverside’s fourth add-on for its global pharma services platform Red Nucleus in 2022
- Riverside first invested in Red Nucleus in December 2019
- Jupiter was founded in 2015
Red Nucleus, which is backed by Riverside Company, has invested in Jupiter Life Science Consulting, a provider of commercial and market access strategies for global pharma, biotech and medical device companies. No financial terms were disclosed.
The acquisition is Riverside’s fourth add-on for its global pharma services platform Red Nucleus in 2022, and ninth add-on since investing in December 2019.
Red Nucleus is a provider of strategic learning and development, scientific services and advisory, and medical communications solutions exclusively for the life sciences industry.
Jupiter was founded in 2015.
“We are thrilled to welcome Jupiter Partners Steve, Ted, Michael and the rest of the Jupiter team into the Red Nucleus family and have strong conviction that the combination will help maximize value for our biopharma customer base,” said Riverside Vice President Mark Fishman, in a statement. “We look forward to continue investing in the high-growth Jupiter team and enabling further expansion in their service offering and geographic scope.”
Working with Tsang and Fishman on the deal for Riverside were Senior Associate Ben Wilson, Associate Armando Torres Jr., Associate Peter Muncey, Operating Partner J.P. Fingado, Operating Finance Executive Rob Carraway and Capital Markets Senior Partner Anne Hayes. Principal, Origination, Grant Marcks sourced the deal for Riverside.